Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics following the company's announcement of disappointing interim results from its Phase 2 bladder cancer trial. The update revealed a 12-month response duration estimate of only 25%, which led to an 80.56% drop in enGene's stock price on May 7, 2026. The law firm is examining whether enGene and its executives engaged in securities fraud or other unlawful practices. Investors affected by the stock decline are encouraged to contact Pomerantz LLP for potential class action participation.
Wayne Jobson, a Grammy-winning producer and filmmaker, discussed his career and influence on reggae and mainstream music in a recent Echoes Across Time podcast. He highlighted his work with Bob Marley, No Doubt, and contributions to major film soundt...
Batmobile Racing has revealed a striking new car design for the Lamborghini Super Trofeo Asia race at Fuji Speedway, supported by new partnerships with Fasoul and Lightec. Leading the Pro category, drivers William Tregurtha and Jonathan Cecotto aim t...
Batmobile Racing has launched a bold new livery for their Car #3, backed by partnerships with Fasoul and Lightec, for the Lamborghini Super Trofeo Asia round at Fuji Speedway. Leading the Pro category, drivers William Tregurtha and Jonathan Cecotto a...
Fluency has issued a notice advising journalists and readers to disregard its previous news release from June 11, 2026, which claimed that CVS was using Fluency to close an enterprise AI deployment gap. This retraction suggests the earlier announceme...
Pepeto's presale is rapidly advancing, attracting significant attention as its exchange and cross-chain bridge near completion. The project uses secure lock and mint technology to enable token swaps across Ethereum, BNB Chain, and Solana, promising z...
